Analytical Data
-
Gene name
MBC2
- Application
-
Alternative Names
Membrane-bound C2 domain-containing protein
-
Species
Human
-
Source
E. coli
-
Tag
N- GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9BSJ8
-
Expression Region
1-245aa
-
Molecular Weight
53.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MBC2, or Myelin Basic Protein Cloning 2, is a key protein involved in the formation and maintenance of myelin sheaths in the central nervous system. Research on MBC2 recombinant proteins has gained attention due to their potential implications in demyelinating diseases such as multiple sclerosis and leukodystrophies. As myelin is crucial for efficient nerve impulse conduction, understanding the structure and function of MBC2 can provide insights into the mechanisms underlying myelin formation and repair. Recombinant MBC2 proteins are engineered to study their biochemical properties, interactions with other myelin components, and roles in signaling pathways related to myelination. Moreover, the ability to produce MBC2 in a laboratory setting allows for extensive characterization, enabling researchers to assess its potential as a therapeutic target or biomarker in neurological disorders. Advances in recombinant DNA technology have facilitated the large-scale production of MBC2, paving the way for functional studies and drug development strategies aimed at restoring myelin integrity in affected patients. Overall, the study of MBC2 recombinant proteins represents a significant step towards unraveling the complexities of myelin biology and developing novel therapeutic approaches for demyelinating diseases.
